Cardano Risk Management B.V. Sells 9,364 Shares of Merck & Co., Inc. $MRK

Cardano Risk Management B.V. trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 1.0% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 970,317 shares of the company’s stock after selling 9,364 shares during the quarter. Merck & Co., Inc. accounts for about 1.0% of Cardano Risk Management B.V.’s holdings, making the stock its 27th largest holding. Cardano Risk Management B.V.’s holdings in Merck & Co., Inc. were worth $124,686,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Lexington Hill Partners LLC bought a new stake in Merck & Co., Inc. in the 2nd quarter worth approximately $299,000. Pine Haven Investment Counsel Inc grew its position in Merck & Co., Inc. by 0.6% during the second quarter. Pine Haven Investment Counsel Inc now owns 14,273 shares of the company’s stock valued at $1,834,000 after acquiring an additional 86 shares during the last quarter. Ledgewood Wealth Advisors LLC bought a new position in Merck & Co., Inc. during the second quarter valued at approximately $201,000. Affinity Capital Advisors LLC raised its stake in shares of Merck & Co., Inc. by 2.2% during the second quarter. Affinity Capital Advisors LLC now owns 4,984 shares of the company’s stock worth $632,000 after acquiring an additional 107 shares in the last quarter. Finally, Valeo Financial Advisors LLC raised its stake in shares of Merck & Co., Inc. by 1.7% during the second quarter. Valeo Financial Advisors LLC now owns 54,116 shares of the company’s stock worth $6,954,000 after acquiring an additional 893 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Recent approvals and label-expansion efforts for KEYTRUDA and ENFLONSIA, together with Merck’s raised 2026 revenue outlook, are reinforcing the investment case. One analysis estimates the shares may still be modestly undervalued after a strong recent run. Merck Could Be Undervalued on Raised Outlook and Approvals
• Positive Sentiment: Positive cancer-drug trial readouts and broader strength across biotechnology and pharmaceutical stocks could support investor interest in Merck’s oncology portfolio and pipeline. These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
• Neutral Sentiment: An industry report identifies continued opportunities in endometrial cancer, including frontline immunotherapy combinations, companion diagnostics and precision therapies. The report highlights Merck as a participant but does not announce a new company-specific deal or result. Endometrial Cancer Market Share Analysis and Industry Trends
• Negative Sentiment: Three Merck executive vice presidents reported selling a combined 86,553 shares for approximately $11.2 million. The transactions reduced their individual holdings by roughly 24% to 62%, which may weigh on sentiment, although insider sales do not necessarily indicate a change in company fundamentals. Chirfi Guindo SEC Form 4 David Michael Williams SEC Form 4 David R. Maraldo SEC Form 4
• Negative Sentiment: Merck is working to diversify beyond KEYTRUDA ahead of its expected 2028 patent expiration. The need for acquisitions, partnerships and new growth platforms underscores the long-term revenue risk associated with the company’s largest product. Merck Is Racing Beyond KEYTRUDA

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on MRK shares. Bank of America upped their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Barclays lifted their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. CICC Research assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price target for the company. Guggenheim upped their price target on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Thirteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $134.56.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $128.61 on Friday. The company has a market capitalization of $317.64 billion, a P/E ratio of 102.89, a PEG ratio of 5.54 and a beta of 0.19. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.05. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The stock has a 50 day moving average price of $123.98 and a two-hundred day moving average price of $119.11.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The firm had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter last year, the business earned $2.13 earnings per share. The business’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts expect that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Insiders Place Their Bets

In other news, EVP David Michael Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares of the company’s stock, valued at approximately $6,106,303. This represents a 24.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 86,553 shares of company stock valued at $11,177,945 in the last quarter. Insiders own 0.17% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.